Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Potassium bicarbonate/potassium citrate - Advicenne

Next Previous
Drug Profile

Potassium bicarbonate/potassium citrate - Advicenne

Alternative Names: ADV 7103; Potassium citrate monohydrated/potassium hydrogen carbonate; Potassium citrate/potassium bicarbonate; Potassium hydrogen carbonate/potassium citrate monohydrated; Potassium-bicarbonate/potassium-citrate-Advicenne; Sibnayal

Latest Information Update: 26 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advicenne
  • Class Alkalinising agents; Citrates; Electrolytes; Potassium compounds; Small molecules; Urologics
  • Mechanism of Action Electrolyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystinuria; Kidney disorders
  • New Molecular Entity No
  • Available For Licensing Yes - Kidney disorders

Highest Development Phases

  • Marketed Kidney disorders
  • Phase II/III Cystinuria

Most Recent Events

  • 18 Mar 2025 Advicenne completes a phase I trial for Healthy volunteers in France (PO) (CTIS2024-518764-13-00)
  • 25 Feb 2025 Advicenne initiates enrolment in a phase I trial for Healthy volunteers in France (PO) (CTIS2024-518764-13-00)
  • 13 Jan 2025 No development reported - Phase-II/III for Cystinuria (In adolescents, In children, In the elderly, In infants, Treatment-experienced, In adults) in Belgium (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top